pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›NOREPINEPHRINE BITARTRATE
drug
save

NOREPINEPHRINE BITARTRATE

Marketedupdated 3mo ago
by Inforlife SA
Approved
community read0 votes

🐶 often sniffed alongside

top 7
  • drugNOREPINEPHRINE BITARTRATE IN 5% DEXTROSE34 co-mentions · 13 sources
  • drugNOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE34 co-mentions · 13 sources
  • drugNorepinephrine Bitartrate Baxter34 co-mentions · 13 sources
  • drugnorepinephrine34 co-mentions · 13 sources
  • tagApproval32 co-mentions · 9 sources
  • drugRNS-6018 co-mentions · 10 sources
  • tagRecall4 co-mentions · 4 sources

all catalysts(8)

approval · 8
Jan 15, 2021
approval
6y ago
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE) — FDA approval
NOREPINEPHRINE BITARTRATE
→
Jun 2, 2022
approval
4y ago
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE) — FDA approval
NOREPINEPHRINE BITARTRATE
→
Jun 2, 2022
approval
4y ago
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE) — FDA approval
NOREPINEPHRINE BITARTRATE
→
Nov 23, 2023
approval
3y ago
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE) — FDA approval
NOREPINEPHRINE BITARTRATE
→
Jun 11, 2024
approval
2y ago
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE) — FDA approval
NOREPINEPHRINE BITARTRATE
→
Dec 11, 2025
approval
8mo ago
NOREPINEPHRINE BITARTRATE — FDA approval
NOREPINEPHRINE BITARTRATE
→
Feb 6, 2026
approval
6mo ago
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE) — FDA approval
NOREPINEPHRINE BITARTRATE
→
Mar 26, 2026
approval
5mo ago
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE (NOREPINEPHRINE BITARTRATE) — FDA approval
NOREPINEPHRINE BITARTRATE
→
view all 8 catalysts →

Patent cliff

source: FDA Orange Book
first barrier falls
Feb 26, 2035
~8.5 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (36)

  • Mar 8, 2041formulationUS 12097170
  • Mar 8, 2041formulationUS 12097170
  • Mar 8, 2041formulationUS 12097170
  • Mar 8, 2041formulationUS 12290494
  • Mar 8, 2041formulationUS 12290494
  • Apr 26, 2039formulationUS 10888534
  • Apr 26, 2039formulationUS 10888534
  • Apr 26, 2039formulationUS 10888534
  • Apr 26, 2039formulationUS 10888534
  • Jan 30, 2038formulationUS 10159657
  • Jan 30, 2038formulationUS 10159657
  • Jan 30, 2038formulationUS 10159657
  • Jan 30, 2038formulationUS 10226436
  • Jan 30, 2038formulationUS 10226436
  • Jan 30, 2038formulationUS 10226436
  • Jan 30, 2038formulationUS 10420735
  • Jan 30, 2038formulationUS 10420735
  • Jan 30, 2038formulationUS 10420735
  • Jan 30, 2038formulationUS 10568850
  • Jan 30, 2038formulationUS 10568850
  • Jan 30, 2038formulationUS 10568850
  • Jan 30, 2038formulationUS 11413259
  • Jan 30, 2038formulationUS 11413259
  • Jan 30, 2038formulationUS 11413259
  • Jan 30, 2038formulationUS 11602508
  • Jan 30, 2038formulationUS 11602508
  • Jan 30, 2038formulationUS 11602508
  • Jan 30, 2038formulationUS 12245996
  • Jan 30, 2038formulationUS 12245996
  • Jan 30, 2038formulationUS 12245996
  • Feb 26, 2035formulationUS RE49422
  • Feb 26, 2035formulationUS RE49422
  • Feb 26, 2035formulationUS RE49422
  • Feb 26, 2035formulationUS RE49422
  • Feb 26, 2035formulationUS RE49443
  • Feb 26, 2035formulationUS RE49443

News(0)

no news has mentioned this drug yet

brand
NOREPINEPHRINE BITARTRATE
generic
NOREPINEPHRINE BITARTRATE
indication
Hypotension
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 20m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?